Abstract
There have been significant advances in the treatment of psychiatric disease in the last half century, but it is still unclear which neural circuits are ultimately responsible for specific disease states. Fortunately, technical limitations that have constrained this research have recently been mitigated by advances in research tools that facilitate circuit-based analyses. The most prominent of these tools is optogenetics, which refers to the use of genetically encoded, light-sensitive proteins that can be used to manipulate discrete neural circuits with temporal precision. Optogenetics has recently been used to examine the neural underpinnings of both psychiatric disease and symptom relief, and this research has rapidly identified novel therapeutic targets for what could be a new generation of rational drug development. As these and related methodologies for controlling neurons ultimately make their way into the clinic, circuit-based strategies for alleviating psychiatric symptoms could become a remarkably refined approach to disease treatment. © 2014 McDevitt et al. This work is published by Dove Medical Press Limited.
Author supplied keywords
Cite
CITATION STYLE
McDevitt, R. A., Reed, S. J., & Britt, J. P. (2014, July 22). Optogenetics in preclinical neuroscience and psychiatry research: Recent insights and potential applications. Neuropsychiatric Disease and Treatment. Dove Medical Press Ltd. https://doi.org/10.2147/NDT.S45896
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.